Cysteine String Protein alpha (CSPα) is a palmitoylated, synaptic vesicle co-chaperone that is essential for neuroprotection. Two mutations in CSPα -L115R and L116Δ -cause adult neuronal ceroid lipofuscinosis (ANCL), a dominantly-inherited neurodegenerative disease. To elucidate the pathogenesis of ANCL, the intrinsic biochemical properties of human wildtype (WT) and disease mutant CSPα were examined. Mutant proteins purified from Escherichia coli exhibited high potency to oligomerize in a concentration, temperature, and time dependent manner, with L115R possessing the greatest potency. When freshly purified, ANCL mutant proteins displayed normal co-chaperone activity and substrate recognition similar to WT. However, co-chaperone activity was impaired for both CSPα mutants upon oligomerization. When WT and mutant CSPα were mixed together they co-oligomerized leading to an overall decrease of co-chaperone activity. The oligomerization properties of ANCL mutants were faithfully replicated in HEK 293T cells. Interestingly, the oligomers were covalently tagged by ubiquitination instead of palmitoylation. Taken together, ANCL mutations result in both a gain and partial loss-of-function.
Introduction
Neuronal ceroid lipofuscinoses (NCLs) are inherited, progressive neurodegenerative diseases that occur mainly in children, and on occasion, also in adults. They are characterized clinically by gait abnormalities, seizures, and dementia. Morphologically, NCLs are identified by the lysosomal accumulation of autofluorescent storage material (lipofuscin) and the loss of neurons, predominantly in the cortex and cerebellum [1] [2] [3] . To date, mutations in 14 genes have been identified to cause NCLs [4] . All, but one, CLN4/DNAJC5 encoding a mutant Cysteine String Protein alpha (CSPα), are familially inherited in an autosomal recessive manner. While the disruption of normal protein function by nonsense or missense mutations has been demonstrated to underlie the pathogenesis of autosomal recessive NCL, little has been known about the unique autosomal dominant form of NCL (CLN4) [5, 6] .
CSPα is a co-chaperone enriched in the presynaptic terminal. It is highly conserved among mammals [7] (Fig. 1 ). CSPα has 3 domainsan N-terminal J-domain, the middle cysteine string domain which is palmitoylated on 14 cysteines, and a C-terminal substrate binding domain (Fig. 1A) . CSPα forms a chaperone complex with Hsc70 and the tetratricopeptide protein SGT, and plays a crucial role in synapse maintenance by acting on select substrates [7] [8] [9] . These include SNAP-25 and dynamin 1, which are essential for synaptic vesicle recycling [10] [11] [12] . The two mutations (L115R and L116Δ) that cause ANCL are in the cysteine string domain [13] [14] [15] (Fig. 1B) . As the name indicates ANCL is a late-onset, dominant form of NCL.
Little is known about the pathogenesis of ANCL. The previous molecular study on ANCL suggests that the two L115R and L116Δ mutations interfere with palmitoylation of CSPα [16] . Even so, ANCL CSPα mutants were shown to aggregate in a palmitoylation dependent manner when heterologously overexpressed with palmitoyltransferases [16] . This raises the question of how the ANCL mutant proteins intrinsically behave. In this study, we purified WT and ANCL mutant CSPα proteins from Escherichia coli and systemically examined their co-chaperone activity, dynamics of oligomerization, and subsequently confirmed these findings in mammalian cell lines. Remarkably, our results show that oligomerization of mutant CSPα can occur even in the absence of palmitoylation and leads to a loss-of-co-chaperone function.
The italic letters in brackets indicate the original nucleotides. The amplified mutant plasmids were confirmed by sequencing.
Construction of plasmids
All site-directed mutagenesis were performed on CSPα sequences subcloned into either PGEX-KG or lentiviral expression plasmids. To insert Myc or FLAG tags upstream of CSPα in lentiviral expression plasmids, XbaI was used to excise the vector and ligated with the annealed oligonucleotides encoding Myc or FLAG. The start codon ATG of CSPα was then removed by site-directed mutagenesis as above. The inserted oligonucleotides are as follows:
Myc: Sense 5′-CTAGAATGGAACAAAAACTTATTTCTGAAGAAGATC TG; Antisense 5′-CTAGCAGATCTTCTTCAGAAATAAGTTTTTGTTCCATT; FLAG: Sense 5′-CTAGAATGGATTACAAGGATGACGATGACAAG; Antisense 5′-CTAGCTTGTCATCGTCATCCTTGTAATCCATT. The primers for site-directed mutagenesis are as follows: Myc-CSPα ATG deletion:
C G LLT C C YC C C C LC C C FN C C C G K C 1 11 J-domain Cysteine String Domain C-terminal Sense: 5′-GAAGATCTGCTAGAC(ATG/Δ)GCTGACCAGAGGCAG; Antisense: 5′-CTGCCTCTGGTCAGC(CAT/Δ)GTCTAGCAGATCTTC. FLAG-CSPα ATG deletion: Sense: 5′-CGATGACAAGCTAGAC(ATG/Δ)GCTGACCAGAGGCAGC; Antisense: 5′-GCTGCCTCTGGTCAGC(CAT/Δ)GTCTAGCTTGTCATCG.
To generate the J domain deletion CSPα construct an XbaI restriction site with an additional a nucleotide C was inserted downstream base pair 246 of CSPα PGEX-KG plasmid by site-directed mutagenesis. The J domain fragment was excised out by XbaI digestion and the final CSPα construct without the J domain was obtained by a subsequent re-ligation. The primers for site-directed mutagenesis are as follows:
Sense: 5′-CAAGTATGGCTCGCTG(TCTAGAC)GGGCTCTATGTGGCTG; Antisense: 5′-CAGCCACATAGAGCCC(GTCTAGA)CAGCGAGCCATA CTTG.
All clones were confirmed by sequencing.
Protein purification
GST-Hsc70, GST-WT, and mutant GST-CSPα were expressed in BL21(DE3) E. Coli and purified as previously described [12] . GST tags were cleaved with thrombin and removed by affinity chromatography. His tagged SGT was purified using Ni-NTA agarose beads based on the description in the manual (QIAGEN). To prevent disulfide bond formation, 2 mM TCEP or DTT was added to the purified proteins. The concentration of the protein preparations was obtained spectrophotometrically. Purified protein was aliquoted and stored at −80°C before use.
Immunoblotting
Equal amounts for purified protein were loaded for SDS-PAGE, while for HEK 293 T cell lysates equal volumes were loaded. The proteins were probed first with specific primary antibodies and then with IRDye conjugated secondary antibodies. Protein bands were quantified on a LI-COR Odyssey infrared imaging system. All CSPα bands over 53 kDa were selected and quantified as HMW oligomers.
ATPase assay
ATPase activity was assayed using a colorimetric approach as described by Chamberlain and Burgoyne [17] . Prior to the start of the ATPase assay, 40 μM of purified WT and mutant CSPα (or a mixture of 20 μM of each) was pre-warmed for 1 min or for 24 h at 37°C. Purified protein (1 μmol) was incubated in ATPase assay buffer (10 mM MgCl 2 , 5 mM KCl, 50 mM Tris, pH 7.5) for 5 min, followed by addition of 1 mM ATP to start the reaction. Aliquots (10 μL) of the reaction were withdrawn every 4 min and incubated with 800 μL of MG solution (0.034% malachite green, 1.04% NH 4 -molybdate, 1 M HCl, 0.04% Tween-20) for 1 min and quenched with 100 μL of 34% Na-citrate. OD 650 was measured 5 min after quenching. The experiment was calibrated using 1 mM KH 2 PO 4 and the concentration of free phosphate was calculated based on the equation 1OD 650 = 9.45 nmol Pi.
GST pull-down
WT or ANCL mutant GST-CSPα fusion proteins were purified from E. coli as described [12] . Fusion protein bound to beads was mixed with brain extract (in 20 mM HEPES, pH 7.4, 100 mM NaCl, 1% Triton X-100) and incubated for at least 4 h by rotating at 4°C. Depending on experimental condition, 5 mM ADP or ATP was added to the mixture as noted. The beads were then washed 3 times for 10 min with HEPES buffer containing 1% Triton X-100 and finally eluted with SDS-PAGE sample buffer by boiling for 10 min.
Immunoprecipitation
HEK 293T cells expressing WT or mutant CSPα were lysed in IP buffer [20 mM HEPES, pH 7.4, 100 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1% Triton X-100, 1 mM PMSF, pepstatin (1 μg/mL), aprotinin (2 μg/mL), leupeptin (1 μg/mL)] and rotated for overnight at 4°C. The lysate was spun for 15 min at 11,300 g and the supernatant was pre-cleared by incubating with washed Protein A with rotation for 1 h at 4°C. The pre-cleared supernatant was incubated with the denoted antibody for 1 h at 4°C and then with washed Protein A beads for 1.5 h at 4°C. The beads were then washed five times with 1 mL of IP buffer, and the bound proteins were eluted by boiling 10 min in SDS-PAGE sample buffer.
Cell culture and transfection
HEK 293T cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin and grown to 80% confluency in 25 cm 2 flasks. Cells were split into 6-well dishes and transfected using GenePORTER3000 lipid reagent, based on the provided protocol. Protein was harvested 48 h after transfection in homogenization buffer [(20 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM PMSF, pepstatin (1 μg/mL), aprotinin (2 μg/mL), leupeptin (1 μg/mL), 1% Triton X-100)].
Statistics
All values are presented as the mean ± SEM, and p b 0.05 was considered statistically significant. Calculations were performed using the GraphPad Prism 4 software (San Diego, CA).
Results

Intrinsic oligomerization of CSPα mutants
We generated ANCL mutants by site-directed mutagenesis ( Fig. 1 ) and characterized the biochemical properties of these proteins. As the ANCL mutations abolish palmitoylation of CSPα [14, 16] , we decided to explore the inherent properties of WT and mutant human CSPα proteins without lipid posttranslational modifications. WT and ANCL mutant CSPα proteins were overexpressed in BL21(DE3) E. coli, which like all bacterial strains lack the eukaryotic palmitoyltransferase enzymes needed to covalently attach palmitates to cysteine residues. Purified proteins (1 mg/mL) were subject to SDS-PAGE in the presence of 50 mM of DTT as previous studies have showed that oligomers of WT CSPα are SDS-resistant [18] . Coomassie staining and immunoblotting of purified proteins indicated that the protein purity exceeded 95% ( Fig. 2A, D) . The gels show that both L115R and L116Δ mutants exhibit noticeable oligomerization compared with the WT CSPα ( Fig. 2A, B, D, E) . Strikingly, oligomerization occurred even in the presence of 1000 fold molar excess reducing agent, suggesting that it is not due to the formation of disulfide bonds by the unpalmitoylated, free cysteines ( Fig. 2A, D; Fig. S1 ). In the absence of DTT, both WT and mutant CSPα show a similar protein smear-like pattern as would be expected from non-specific disulfide bond formation (Fig. S1 ). The addition of DTT abolished the smear except for the specific oligomers seen in the case of ANCL mutants (Fig. S1 ).
Distinct oligomeric species were seen with the two ANCL mutants. The size of the oligomers for the L115R mutant were~56,~100 and 250 kD, corresponding to dimer, tetramer and species with 8 or more monomers, while the size of the oligomer for the L116Δ mutant was~250 kD ( Fig. 2A, D) . The dissimilar banding pattern suggests that the oligomerization behavior of L115R and L116Δ is different, but generates at least one common oligomeric~250 kD species. As shown in Fig. 2E , the L115R mutant also produced higher molecular weight (HMW) oligomers (58.9 ± 5.9 fold versus WT) than the L116Δ mutant (13.2 ± 3.9 fold versus WT). In the case of L115R, oligomerization was accompanied by an observable loss of monomeric protein (0.28 ± 0.03 fold versus WT; Fig. 2C and F). Taken together, both CSPα mutants are prone to oligomerize and form HMW oligomers which were DTT resistant, but the L115R mutant has the highest propensity to do so. Importantly, the oligomerization occurs in the absence of palmitoylation.
Given that both ANCL mutations are located in the proximity of cysteine string domain, we investigated whether the flanking domains, i.e. the J domain and C terminus ( Fig. 1A; Fig. S2A ), affect the oligomerization of CSPα mutants. We generated WT and mutant, J domain and C terminus deletions, and confirmed that we successfully deleted the relevant domains by staining with CSPα N terminus and C terminus epitope specific antibodies (Fig. S2C, D) . As shown in Fig. S2 , neither deletion of the J domain nor C terminus inhibits the oligomerization of the ANCL mutants (Fig. S2B, F) . In fact, the deletion of the J-domain increased the abundance of oligomers for both WT and ANCL CSPα (Fig. S2B , D and E), indicating a possible inhibitory role. Overall, these data suggest that the cysteine string domain and the ANCL mutations are the key determinants of CSPα oligomerization. Our findings are consistent with the previously published results showing that amino acids 83-138 of WT CSPα, which include the cysteine string domain are important for self-assembly [18] .
Next, we examined whether SGT, a clamp protein that stabilizes the CSPα/Hsc70 chaperone complex, played a significant role in oligomerization of ANCL mutants [7] . Surprisingly, SGT exhibited no effect on oligomerization of CSPα mutants (Fig. S3) , and furthermore SGT was not observed to assemble into CSPα oligomers (Fig. S3A , B and D). These data suggest that oligomerization is an intrinsic protein property of ANCL mutant CSPα.
Characterization of oligomerization properties of mutant CSPα
For familiar neurodegenerative disease proteins such as Aβ and α-synuclein, it has been well established that increased protein concentration accelerates oligomerization and aggregation of mutant proteins [19, 20] . To test whether CSPα behaved similarly, we prepared solutions of increasing protein concentrations (0.125-1.0 mg/mL; 5-40 μM) and subject them to SDS-PAGE and immunoblotting. Fig. 3A -C shows that raising protein concentration significantly augmented HMW oligomers and reduced monomer amounts for L115R. The three dominant species showed different concentration dependence with the~100 and~250 kD species exhibiting a significant increase with concentration ( Fig. S4 ) while the~56 kD did not, suggesting that the species N100 kD arise from monomers directly (Fig. S4 ). For the L116Δ mutant, we only observe the formation of the 250 kD species at a concentration of 1 mg/mL (Fig. 3A, B ) and the monomer levels displayed a mild decrease compared with WT ( Fig. 3C) .
Another property for neurodegenerative associated proteins is their temperature dependence of oligomerization and aggregation [21] . Since the above western blots were performed after boiling the samples, two other temperatures, 37°C and 69°C, were chosen to treat the proteins prior to separation on SDS-PAGE. As seen in Fig. 3D -F, oligomeric intermediates were formed for L115R at all temperatures tested. Interestingly, WT and L116Δ form novel oligomeric species at 37°C, several of which are shared with L115R, but these intermediates are abolished with the exception of the 250 kD species, upon increasing the temperature (Fig. 3D) . Consistent with this, the monomer levels were increased as a function of temperature, reflecting an imbalance between the disassembly of non-specific oligomers and formation of mutant specific species (Fig. 3F and Fig. S1 ). The quantification of the CSPα band at 250 kD reveals that its levels increase with temperature for both mutants (Fig. 3E) . The temperature dependence mirrors the concentration dependence of oligomer formation for the two ANCL mutants (Fig. 3B, E) , again indicating different propensity to oligomerize.
To investigate this further, we varied the time of incubation at 37°C. As shown in aspect is that the oligomer pattern obtained after incubating mutant proteins at 37°C for 24 h mimics that at 100°C for 10 min (Fig. 3G versus Fig. 2D ). In these samples, the 250 kD species predominates indicating that this is a physiologically relevant species. We also did not observe macroscopic aggregates. In all, our data support the principle that oligomerization of CSPα mutants, like other neurodegenerative disease proteins, is concentration and time-dependent.
Co-chaperone function is impaired by oligomerization of CSPα mutants
CSPα functions as co-chaperone through its interactions with Hsc70 and its substrates [7, 12] . We wanted to explore whether the ANCL mutations impact co-chaperone function of CSPα directly or indirectly through increased protein oligomerization. First, we determined the effect of ANCL mutations on freshly purified protein preparations which have equivalent amounts of monomeric proteins (Fig. 4A-D) . We measured the ability of the CSPα mutants to accelerate the ATPase activity of Hsc70, via their J-domains. WT CSPα can readily accelerate the basal ATPase activity of Hsc70 by 2.5 fold consistent with the previously published results (Fig. 4A) [12, 22] . As a negative control, we used a J-domain mutant (CSPα QPN) which has diminished Hsc70 binding and impaired ability to stimulate the ATPase activity of Hsc70 [12] . Remarkably, both the L115R and L116Δ mutants could robustly accelerate the ATPase activity of Hsc70 to the same level as WT protein (Fig. 4A, D) . These enzymatic assay results indicate that the J-domain of the ANCL mutants can bind Hsc70 and is functional. Next, we examined the functionality of the C-terminal domain by assessing the ability of the ANCL mutants to bind specific CSPα clients. We tested binding to the two best characterized clients of CSPα-SNAP-25 and dynamin 1 [11, 12] by performing affinity chromatography using mouse brain homogenates. These experiments clearly demonstrate that the ANCL mutants can bind client proteins as effectively as WT CSPα (Fig. 4E) . This biochemical interrogation revealed that ANCL CSPα mutants, when not oligomerized, are functional as co-chaperones. This is consistent with the fact that both ANCL mutations are in cysteine string domain and not in the J-or C-terminal domain.
To study the impact of oligomerization on CSPα co-chaperone activity, we incubated WT and ANCL mutant CSPα for 24 h at 37°C, followed by Hsc70 ATPase assays. The L115R mutant's ability to stimulate Hsc70 ATPase activity was dramatically reduced by 80%, but no significant difference was observed for the L116Δ mutant compared with WT (Fig. 4F) . The co-chaperone capacity of these protein preparations largely reflects the amount of monomer protein remaining, as only 10% of L115R but still 66% of L116Δ monomer was left after 24 h (Fig. 4G, H) . Nonetheless, the decrease in monomer levels is more affected than enzymatic activity, and can be seen by normalizing ATPase activity to CSPα monomers amount (Fig. 4I) . This implies that perhaps dimeric CSPα species retain ATPase stimulatory activity as suggested previously [17] , while other HMW oligomers are not functional.
Co-oligomerization of WT and mutants attenuates co-chaperone activity of CSPα
ANCL occurs in the heterozygous state with one copy each of WT and mutant CSPα. To model the disease condition, we mixed WT and ANCL mutants in a 1:1 M ratio (0.5 mg/mL), and incubated the proteins for 24 h at 37°C. We first examined the oligomeric profiles of the mixtures and compared it to the individual proteins. Intriguingly, both ANCL mutants when mixed with WT protein formed the 250 kDa species, even though both WT and L116Δ individually did not do so under these lower protein conditions (Fig. 5A) . Quantifications confirmed that the WT:ANCL mixtures do indeed oligomerize to a greater extent (Fig. 5B) and are accompanied by a larger loss of monomer (Fig. 5C) . Next, we used these mixtures to test their efficacy in the Hsc70 ATPase assays and compared them to the same proteins incubated alone. We observed that ATPase activity of the mixtures was significantly lower than what one would expect from the sum of the individual protein activity (Fig. 5D ). This would suggest that the mixtures oligomerize to a greater extent and that hetero-oligomers of WT and ANCL mutants are not enzymatically active. It is important to note that both the L115R and L116Δ mutants behave similarly in the presence of WT protein, consistent with the similar phenotypes seen in patients. 
Oligomerization of CSPα mutants in HEK 293T cells
Our experiments using purified proteins suggest that oligomerization is an intrinsic property of ANCL CSPα mutants. This raises the question whether this is purely an in vitro phenomenon or could also occur in mammalian cells. To examine this matter, WT and the ANCL proteins were overexpressed in HEK 293T cells. Cell lysates were incubated at 37°C, separated on SDS-PAGE and blotted for CSPα (Fig. 6A-C) . Both ANCL mutants exhibited observable oligomerization, (Fig. 6A) , resembling the purified proteins in vitro (Fig. 1A, D) . Consistent with the purified protein data (Fig. 2) , all oligomeric intermediates shifted to the top of the gel when the samples were boiled (Fig. 6D-F) .
In HEK 293T cells, the palmitoylation of monomers was severely impaired for the ANCL mutants ( Fig. 6A, D ; S5) in line with previous reports [16] . To test if the oligomers were palmitoylated, an aliquot of the same HEK 293T cell lysate was treated overnight at 4°C with hydroxylamine (HA), a chemical that depalmitates proteins. A slight decrease in oligomers and increase of monomers were detected for the L115R (0.9 ± 0.016 fold of HMW/monomer versus 'No HA') and L116Δ mutants (0.95 ± 0.02 fold of HMW/monomer versus 'No HA') ( Fig. 6F) , with only a few selected bands disappearing upon hydroxylamine treatment, even though the WT monomeric CSPα was completely depalmitoylated under these conditions (Fig. 6A, D) . This suggests that in HEK 293T cells, ANCL CSPα oligomers were largely not palmitoylated. Next, we tested if the soluble oligomers formed insoluble macroscopic aggregates, as seen in other dominantly inherited neurodegenerative diseases. Pellet fractions from transfected HEK 293T cells were subject to centrifugation steps to enrich for aggregates and solubilized in 8 M urea containing sample buffer. Neither monomer nor oligomer was present in the pellet (data not shown), suggesting no insoluble aggregates were formed. This finding is congruent with the lack of overt CSPα neuropathology in ANCL brains [14] . The similarity of oligomerization of CSPα mutants both in vitro and in mammalian cells indicates that CSPα oligomers are indeed newly gained species in ANCL. concomitant decrease in co-chaperone activity (Fig. 5) . However, we cannot exclude that the oligomers are derived only from the mutant rather than from both WT and mutant. To test whether the ANCL mutant proteins are capable of forming mixed oligomers with the WT protein, we used FLAG and Myc tagged CSPα constructs and coexpressed them in HEK 293T cells. Western blotting with FLAG or Myc antibody confirmed that the tagged proteins behave similar to untagged versions, with the ANCL mutants forming 250 kD oligomers to a greater extent than WT CSPα (Fig. 7A , B, E, F versus Fig. 6D, E) . The co-expression of Myc tagged WT with FLAG tagged mutant and vice versa significantly promoted the formation of WT oligomers (Fig. 7C, D, G, H) , indicating the formation of mixed oligomers.
Ubiquitination of oligomers formed by both WT and mutant CSPα
The above HEK 293T experiments establish that the ANCL mutants are not palmitoylated and readily oligomerize compared to WT CSPα (Fig. 6 ). Based on these findings, we tested whether CSPα oligomers are selectively targeted for degradation. CSPα proteins were immunoprecipitated from HEK 293T cell lysates and probed with an antibody that recognizes poly-ubiquitination, a covalent modification that targets proteins for degradation. As shown in Fig. 8A , CSPα antibody could immunoprecipitate and enrich both monomers and oligomers. Fascinatingly, the polyubiquitin antibody only significantly recognized the 250 kD band whose signal intensity correlated with the amount of CSPα positive oligomers (Fig. 8B, C) .
Discussion
Gain and loss of function mechanisms underlie ANCL
In this study, we systemically characterized the two ANCL causing mutants-L115R and L116Δ. Unlike other recessive NCL mutations which directly abrogate the normal function of the associated proteins, dominant CSPα mutations had no adverse effect on CSPα co-chaperone activity and substrates binding affinity, instead they drove the formation of novel oligomeric species which in turn disrupted the function of both WT and mutant CSPα. Here we propose that the oligomerization of CSPα mutants is a gain-of-function which directly leads to a loss-offunction based on several observations. 1) The oligomerization of ANCL CSPα mutants occurs extensively and in a time, concentration, and temperature dependent manner (Fig. 3). 2) The loss of cochaperone activity of mutant CSPα depends on protein oligomerization. In the absence of oligomerization, WT and mutant stimulate ATPase activity of Hsc70 equivalently (Fig. 4A) ; indicating that the mutation itself does not affect the inherent function of CSPα. Further, the decrease in CSPα co-chaperone activity largely reflects the loss of monomers by oligomerization (Fig. 4F-H). 3) The co-oligomerization of WT and mutants occurs both in vitro and in mammalian cells (Figs. 5, 7) . Thereby, co-oligomerization makes it feasible for one mutant CLN4/DNAJC5 allele to result in the dysfunction of CSPα protein encoded by both alleles and most likely accounts for the dominant nature of ANCL. 4) In support of a loss-of-function mechanism, we observe mislocalization of both WT and mutant CSPα in the cell body away from synaptic 
P N P N *** *** *** *** * While oligomerization is a common molecular feature of autosomaldominant inherited neurodegenerative diseases-such as Alzheimer's disease, Parkinson's disease, and ALS-for these diseases oligomerization does not appear to result in a loss-of-function. This is supported by the fact that the deletion of the corresponding disease causing genes-APP, α-synuclein and superoxide dismutase 1-from mice genome results in no or subtle phenotype [23] [24] [25] , unlike patients or transgenic mice that overexpress mutant proteins [26] [27] [28] . One dominant neurodegenerative disease clearly shown to be caused by both a gain and partial loss-of-function is spinocerebellar ataxia 1 [29] . Mutations in ataxin 1 cause spinocerebellar ataxia 1, but do not involve protein oligomerization. In marked contrast to these neurodegenerative diseases, in ANCL, an oligomerization dependent loss-of function is likely to underlie its pathogenesis as CSPα knockout mice phenocopy ANCL patients. CSPα knockout mice show progressive neurodegeneration and exhibit phenotypes such as seizures, motor deficits, and premature death seen in patients. Our data adds to growing evidence that for dominantly inherited neurodegenerative diseases, multiple mechanisms of action are likely to underlie disease pathophysiology.
Though we have clearly demonstrated an oligomerization-dependent loss of CSPα co-chaperone activity, it remains possible that the oligomers have additional modes of action. CSPα is a synaptic vesicle associated protein which is synthesized in endoplasmic reticulum (ER), transported to synaptic terminal via the Golgi and degraded in lysosomes [30] . Considering the stringent protein quality control that occurs at the ER, a question that remains to be addressed is whether oligomerization of CSPα mutants also causes ER stress and subsequently the unfolded protein response [31, 32] . Similarly, possible deleterious effect of oligomers on Golgi and lysosomes needs more investigation. However, these studies are beyond the scope of the present work.
Distinct oligomerization pathways for L115R and L116Δ mutants
Although the L115R and L116Δ mutations are localized to cysteine string domain and even are next to each other, previous in silico analysis had predicted dissimilar alterations on biophysical and biochemical properties of CSPα. In keeping with this, we see clear differences in the oligomerization behavior for the L115R and L116Δ mutants both in terms of magnitude and time dependence. The L115R mutant was predicted to have a weaker membrane affinity which possibly facilitates self-assembly. Consistent with this prediction, we demonstrate that L115R is more potent to oligomerize than L116Δ. Interestingly, L115R patient brains have been shown to have less CSPα protein levels compared to L116Δ brains [14] . The two mutants also differ in the dynamic pattern of oligomerization. The L116Δ mutant resembles the WT oligomer pattern but with a higher abundance, in contrast, the L115R oligomer pattern clearly varies from WT and L116Δ ( Fig. 3D, G;  Fig. 4B, G; Fig. S2B; Fig. S3C ). Yet, both mutants generate at least one common 250 kDa oligomeric species, strongly suggesting that this may be a disease relevant oligomer.
Interestingly, the co-oligomerization of L115R and L116Δ with WT is very similar, in spite of the different potentials for self-assembly. As a consequence, L116Δ appears to be more potent than L115R to cooligomerize with WT CSPα. On the other hand, L115R oligomerization stands out with respect to its ability to self-assemble. Hence, we predict that ANCL patients carrying different mutants might show subtle differences in age of onset, speed of progress and duration of disease.
Post-translational modifications on ANCL mutants
Both ANCL mutations abolish palmitoylation of monomeric CSPα in HEK 293T cells. This is most likely because the leucines mutated in ANCL are needed to target CSPα to the membrane allowing the palmitoylacyltransferases to palmitoylate CSPα [33] . Our findings on the impact of ANCL mutations on palmitoylation are congruent with those reported by Greaves et al. [16] . However, in contrast to the reported work, we do not find any effect of palmitoylation on protein oligomerization. This may be due to the fact that palmitoylacyltransferases were overexpressed to make this point [16] . The fact that recombinantly produced protein from E. coli which lack palmitoylation also aggregates strongly support our case that palmitoylation is not required for ANCL mutant oligomerization. In contrast to a role for palmitoylation, we observed that the 250 kD oligomer is selectively ubiquitinated. It is widely accepted that ubiquitination can serve as a signal for degradation of lysosomes [34] . Hence, we hypothesize that the degradation of CSPα oligomers via lysosomes over time leads to lysosomal dysfunction and lipofuscin deposition.
Conclusion
Here we provide the evidence that ANCL mutants, CSPα L115R and L116Δ, could undergo self-oligomerization and co-oligomerization with WT CSPα. Oligomerization is therefore a gain-of-function as result of these mutations, but leads to a loss of co-chaperone activity of CSPα. Hence, we propose a mechanism involving both a gain-of-function and a loss-of-function of CSPα causes ANCL. Our findings are congruent with the fact that ANCL is a dominant disease and helps explain the phenotypes seen in CLN4 patients. Altogether, our data highlight the role of protein oligomerization in ANCL and suggest that disrupting oligomerization of CSPα mutants may be an effective therapy for treating ANCL.
